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Neuregulin-1 (NRG1), a regulator of neural de-
velopment, has been shown to regulate neuro-
transmission at excitatory synapses. Although
ErbB4,akeyNRG1 receptor, is expressed inglu-
tamic acid decarboxylase (GAD)-positive neu-
rons, little is known about its role in GABAergic
transmission. We show that ErbB4 is localized
at GABAergic terminals of the prefrontal cortex.
Our data indicate a role of NRG1, both endoge-
nousandexogenous, in regulationofGABAergic
transmission. This effect was blocked by inhibi-
tion or mutation of ErbB4, suggesting the in-
volvement of ErbB4. Together, these results
indicate that NRG1 regulates GABAergic trans-
mission via presynaptic ErbB4 receptors, identi-
fying a novel function of NRG1. Because both
NRG1andErbB4haveemergedassusceptibility
genesof schizophrenia, theseobservationsmay
suggest a mechanism for abnormal GABAergic
neurotransmission in this disorder.
INTRODUCTION
Neuregulin-1 (NRG1), a family of polypeptides that plays
an important role in neural development, is implicated in
nerve cell differentiation, neuron migration, neurite out-
growth, andsynapse formation (BuonannoandFischbach,
2001; Corfas et al., 2004). NRG1 and its receptor ErbB
tyrosine kinases are expressed not only in the developing
nervous system, but also in adult brain. In the adult, ErbB
receptors are concentrated at the postsynaptic density
(PSD), presumably via interaction with PDZ domain-
containing proteins including PSD-95 and erbin (Garcia
et al., 2000; Huang et al., 2000, 2001; Ma et al., 2003).
NRG1 suppresses induction of LTP at Schaffer collateral-CA1 synapses in the hippocampus without affecting basal
synaptic transmission (Huang et al., 2000; Ma et al., 2003).
Subsequently, NRG1 was shown to reverse LTP and re-
duce whole-cell NMDA receptor currents in pyramidal
neurons of prefrontal cortex, and was also shown to de-
creaseNMDA receptor-mediated EPSCs in prefrontal cor-
tex slices (Gu et al., 2005; Kwon et al., 2005). Interestingly,
the NRG1 gene is strongly associated with schizophrenia
in diverse populations in Iceland, Scotland, China, Japan,
and Korea (Fukui et al., 2006; Kim et al., 2006; Stefansson
et al., 2002, 2003; Yang et al., 2003).
ErbB4 mRNA is enriched in regions where interneurons
are clustered in adult brains (Lai and Lemke, 1991). GAD-
positive neurons from the embryonic hippocampus ex-
press ErbB4 (Huang et al., 2000). During development,
loss of NRG1/ErbB4 signaling alters tangential migration
of cortical interneurons, leading to a reduction in the num-
ber of GABAergic interneurons in the cortex (Anton et al.,
2004; Flames et al., 2004). In adult mice, deletion of ErbB4
in the central nervous system (CNS) resulted in lower levels
of spontaneous motor activity, reduced grip strength, and
altered cue use in performing a maze task (Golub et al.,
2004). The ErbB4 gene is also associated with schizophre-
nia (Law et al., 2006; Nicodemus et al., 2006).
g-Aminobutyric acid (GABA) is the principal inhibitory
neurotransmitter in the mammalian forebrain. GABAergic
inhibitory interneurons are essential to the proper func-
tioning of the CNS (McBain and Fisahn, 2001). GABAergic
dysfunction is implicated in several neurological disor-
ders, including Huntington’s chorea, Parkinson’s disease,
and epilepsy, and in psychiatric disorders such as anxiety,
depression, and schizophrenia (Coyle, 2004).
This study investigates the role of NRG1 in GABAergic
neurotransmission. We find that ErbB4 is expressed in
GABAergic presynaptic terminals in the cerebral cortex.
Treatment with NRG1 had no effect on basal GABA re-
lease, but it increased evoked release in cortical slices in a
manner dependent on ErbB4. These observations identify
a novel function of NRG1 and may suggest a mechanismNeuron 54, 599–610, May 24, 2007 ª2007 Elsevier Inc. 599
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Neuregulin Regulation of GABAergic TransmissionFigure 1. NRG1 and ErbB4 Are Expressed throughout Cortical Layers
(A–C) In situ hybridization in adult rat brain coronal sections using radiolabeled antisense RNA probes. (A) ErbB4-specific hybridization was detected
in scattered cells throughout the cortex (layers 2–6b) in the rostral forebrain (left panel). Prominent hybridization is observed in scattered cells through-
out the cortex and hippocampus (Hi), in the medial habenula (MHb), in the reticular nucleus of the thalamus (Rt), and in the intercalated masses of the
amygdala (Amyg) in a more caudal section (right panel). Scale bar, 1 mm. (B) In the rostral forebrain (left panel), NRG1 type I/II-specific hybridization
was detected in layers 2-3 and 6b of the cortex and in the piriform cortex (Pir). In caudal sections (right panel), NRG1 type I/II transcripts were detected
in cortical layer 6b, in the reticular nucleus of the thalamus (Rt), in all fields of the hippocampus (Hi), and in scattered large cells in the globus pallidus
(GP). (C) In the rostral forebrain (left panel), NRG1 type III-specific hybridization was detected in cortical layer 5 and in the piriform cortex (Pir). In more
caudal sections (right panel), it was present in cortical layer 5, the reticular nucleus of the thalamus (Rt), and all fields of hippocampus (Hi).for abnormal GABAergic neurotransmission in schizo-
phrenia and epilepsy.
RESULTS
Localization of ErbB4 in GABAergic
Presynaptic Terminals
ErbB4 transcripts were expressed throughout cortical
layers 2–6b (Figure 1A) (Lai and Lemke, 1991; Yau et al.,
2003). In addition, ErbB4 transcripts were identified at
high levels in the medial habenula, the reticular nucleus
of the thalamus, and in the intercalated masses of the
amygdala. These observations are consistent with the no-
tion that ErbB4 is expressed in interneurons. In further
agreement, ErbB4 was shown to be present in GAD-posi-
tive neurons isolated from the hippocampus (Huang et al.,
2000). To determine the in vivo subcellular localization of
ErbB4 in GAD-positive neurons, we stained prefrontal
sections of GFP-expressing inhibitory neurons (GIN) mice
that express GFP under the control of the gad1 promoter
that directs specific expression in GABA interneurons,
especially those that are somatostatin positive, in the hip-
pocampus (Oliva et al., 2000). Presynaptic terminals of
GABAergic neurons appear as discrete puncta-rings in
the prefrontal cortex, surrounding the soma of postsynap-
tic neurons in cortical layers 2–6 (Figure 2A, arrows) (Pillai-
Nair et al., 2005). The anti-ErbB4 antibody 0618 (Zhu et al.,
1995) and sc-283 specifically recognized ErbB4 because
their immunoreactivity was diminished in ErbB4 mutant
mice (Figures 2G and 2H). As shown in Figure 2A, ErbB4
was detected in puncta-rings and neuropils, colocalizing
with GFP. Quantitatively, about 90% of puncta-rings and
neuropils in the prefrontal cortex expressed ErbB4 (Fig-
ure 2B). These results suggest that ErbB4 is present at
terminals of GABAergic neurons, including somatostatin
neurons. To test this hypothesis further, we determined600 Neuron 54, 599–610, May 24, 2007 ª2007 Elsevier Inc.whether ErbB4 colocalizes with GAD65 and vesicular
GABA transporter (VGAT), bothwell-characterizedmarkers
of GABAergic terminals (Tafoya et al., 2006). The ErbB4
immunoreactivity colocalized with GAD65 and VGAT in
puncta-ring-like structures (Figures 2C and 2D). Twenty-
three percent of GAD65 clusters and forty-seven percent
of VGAT clusters were ErbB4-positive, suggesting ErbB4
localization at specific subsets of GABA terminals (Figures
2E and 2F). On the other hand, 26% and 70% of ErbB4
clusters colocalized with GAD65 and VGAT, respectively,
in agreement with the notion that ErbB4 is also localized
at non-GABAergic synapses (Huang et al., 2000). Taken
together, these results indicate that ErbB4 is present at
groups of presynaptic terminals of GABAergic neurons in
the cerebral cortex.
Increase in Depolarization-Evoked GABA
Release by NRG1
The presynaptic localization of ErbB4 in GABAergic neu-
rons suggested to us that NRG1 may regulate GABAergic
neurotransmission. To test this hypothesis, wedetermined
effects of NRG1 on GABA release in cortical slices by both
biochemical and electrophysiological approaches. Basal
[3H]GABA release was low, at a rate of 3.75% ± 0.35%
(n = 8) of total radioactivity per 10 min (Figure 3A). Treat-
ment of sliceswith 20mMKCl, a treatment known to depo-
larize neurons, increased [3H]GABA release by 2.5- to 3.5-
fold within 10min (Figure 3A). NRG1 had no effect on basal
[3H]GABA release; by contrast, it increased depolariza-
tion-evoked GABA release in a dose-dependent manner
(Figures 3A and 3B and Figure S1A in the Supplemental
Data). This effect was not inhibited by antagonists of gluta-
mate receptors, suggesting that the increase in GABA
release does not require glutamatergic signaling (Fig-
ure S1B). To demonstrate that NRG1 regulates the
physiological function of GABA transmission, inhibitory
Neuron
Neuregulin Regulation of GABAergic Transmissionpostsynaptic currents (IPSCs) were recorded from pre-
frontal cortical slices. As shown in Figures 3C–3F, NRG1
did not appear to affect the frequency, amplitude, and de-
cay timesofminiature IPSCs (mIPSCs) thatwereblockable
by bicuculline, a GABA-A receptor antagonist (Figure S1C
and data not shown). These results are in agreement with
observations above that basal GABA release was not af-
fected. By contrast, as shown in Figure 3G, it enhanced
evoked IPSCs (eIPSCs) that were sensitive to bicuculline
(Figure S1D). The increase in eIPSCs had a similar dose-
response curve to that of evoked [3H]GABA release
(Figure 3H) and was abolished when NRG1 was heat-
denatured (Figure 3I). Furthermore, the NRG1 regulation
remained unchanged in the presence of antagonists of
metabotropic glutamate receptors, cholinergic receptors,
serotonin receptors, adrenergic receptors, dopamine re-
ceptors, or some combination thereof (Figure S1E). As a
control, BDNF decreased depolarization-evoked GABA
release and eIPSCs in cortical slices, in agreement with
earlier studies (Canas et al., 2004; Frerking et al., 1998).
These results indicate that NRG1 increases evoked GABA
release without affecting basal release, likely via a direct
effect on GABAergic presynaptic terminals.
NRG1 Effects on GABAergic Presynaptic Terminals
To further determine whether NRG1 regulates GABA re-
lease directly at presynaptic terminals, we performed the
following two experiments. First, we investigated whether
NRG1 is able to regulate [3H]GABA release from synapto-
somes in the absence of their neural circuit. As shown in
Figure 4A, NRG1 increased depolarization-evoked GABA
release from synaptosomes while having no effect on
basal GABA release. Moreover, this effect was concentra-
tion-dependent, with a maximal response of 28% ± 1.5%
(n= 6), similar to that observed in cortical slices (Figure 4A).
Second, we characterized the paired-pulse ratios (PPRs)
of control and NRG1-affected eIPSCs in response to two
stimulations. At inhibitory synapses, a second stimulation
generates a smaller eIPSC because of depletion of vesi-
cles in the releasable pool by the first stimulation (Lambert
and Wilson, 1994). Figure 4B (left panel) shows averaged
traces of eight consecutive eIPSCs induced by paired
stimuli at different interpulse intervals. The PPRs at 25
ms intervals were reduced from 0.86 ± 0.07 in control to
0.68 ± 0.05 in NRG1-treated slices (n = 6, p < 0.01). The
reduction in PPRs remained even at 200 ms intervals.
The depression effect of NRG1 on the amplitudes of the
second eIPSCs provides further evidence that NRG1 reg-
ulates evoked GABA release by a presynaptic mecha-
nism. In addition, these results also suggest that NRG1
may increase the probability of GABA release in response
to depolarization.
Endogenous NRG1 Is Necessary to Maintain
Activity-Dependent GABA Release
NRG1 is expressed in various regions in the brain (Law
et al., 2004). NRG1 type I/II transcripts were detected
prominently in cortical layer 6b and at lower levels in layers2–3 (Figure 1B). In comparison, NRG1 type III transcripts
were primarily detected in cortical layer 5 (Figure 1C). Hy-
bridization of NRG1 type I/II was also observed in the re-
ticular nucleus of the thalamus and in cholinergic interneu-
rons in the globus pallidus. NRG1 type III was expressed in
the reticular nucleus of the thalamus. Both NRG1 isoforms
were also observed in the piriform cortex and throughout
the hippocampus. Notably, the distinct isoforms of NRG1
appear to be expressed in a laminar-specific and largely
nonoverlapping manner in the cortex. These observations
indicate that NRG1 is available in various areas in the brain
including the cerebral cortex. To determine whether en-
dogenous NRG1 regulates GABA release, we generated
ecto-ErbB4, which contains the entire extracellular region
of ErbB4 fused to an FC fragment. Ecto-ErbB4 binds to
and thus prevents NRG1 from interactingwith ErbB recep-
tor kinases.Asshown inFigure5AandFigure5B, treatment
with ecto-ErbB4 inhibited NRG1 activation of ErbB4 in
GAD-positive neurons (see Figure S2 for characterization
of the anti-phospho-ErbB4 antibody). Such treatment
blocked NRG1 potentiation of eIPSCs in a dose-depen-
dent manner (Figures 5C and 5D), demonstrating the
neutralizingability of ecto-ErbB4.NRG1-enhancedevoked
GABAreleasewasalso inhibitedbyecto-ErbB4 (Figure5D).
Remarkably, treatment with ecto-ErbB4 alone reduced
both evoked GABA release and eIPSCs in the absence of
exogenous NRG1 (Figure 5D). These observations and
results from studies of inhibitors of ErbB4 suggest a role
for endogenous NRG1 in regulating evokedGABA release.
ErbB4 Is Necessary for NRG1 Enhancement
of Evoked GABA Release
Of the three ErbB kinases, ErbB2 and ErbB4, but not
ErbB3, are catalytically active (Citri and Yarden, 2006). To
determine which ErbB is involved in NRG1 regulation of
evoked GABA release, cortical neurons were treated with
AG879 and AG1478, specific inhibitors of ErbB2 and
ErbB4, respectively (Fukazawa et al., 2003). ErbB4 tyro-
sine phosphorylation in response to NRG1 was blocked
in neurons pretreated with AG1478, but not AG879 (Fig-
ures 6A and 6B). Treatment with AG1478 prevented
NRG1 from increasing evoked GABA release and increas-
ing amplitude of eIPSCs in cortical slices (Figure 6C).
These results suggest a role of ErbB4 in NRG1 regulation
of GABAergic transmission. As observed with ecto-
ErbB4, AG1478 alone decreased depolarization-evoked
[3H]GABA releaseand theamplitudeof eIPSCs (Figure 6C),
providing further evidence that endogenous NRG1 activity
may be necessary to maintain GABA release elicited by
neuronal activation. In a control experiment, treatment
with AG879 had no detectable effect on evoked GABA
release and the amplitude of eIPSCs in the presence or ab-
sence of exogenous NRG1 (Figure 6C). Taken together,
these observations demonstrate that activation of ErbB4,
but not ErbB2, is required for NRG1’s effect.
To investigate the involvement of ErbB4 further, we
characterizedevokedGABArelease inErbB4mutantmice.
ErbB4 null mutant mice die around E11. The embryonicNeuron 54, 599–610, May 24, 2007 ª2007 Elsevier Inc. 601
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Neuregulin Regulation of GABAergic TransmissionFigure 2. ErbB4 Is Present at Presynaptic Terminals of GABAergic Neurons
(A) Coronal sections of prefrontal cortex of GIN-GFP mice were stained with anti-ErbB4 antibody 0618 (top panels) or with the antibody sc-283 (bot-
tom panels). Immunoactivity was visualized by Alexa 594-conjugated secondary antibody. GAD-positive terminals (expressing GFP) were visualized
by excitation at 488 nm. Arrows, GFP-positive puncta-ring structures surrounding pyramidal neurons; arrowheads, neuropils; inset, enlarged areas.
(B) Quantitative analysis of puncta-rings and neuropils that are positive for ErbB4. The antibody used for quantification was 0618. Shown are means ±
SEM; n = 60 for puncta-rings and n = 10 for neuropils of 20 independent sections.
(C and D) Coronal sections of prefrontal cortex were stained with anti-ErbB4 antibody 0618 and anti-GAD65 (G1166) and anti-VGAT (131003) anti-
bodies. Immunoactivity was visualized by Alexa 488- and Alexa 594-conjugated secondary antibodies, respectively. Arrowheads, colocalization of
ErbB4 and GAD65 or VGAT; arrows, ErbB4-positive alone; hallow arrows, GAD65- or VGAT-positive alone.602 Neuron 54, 599–610, May 24, 2007 ª2007 Elsevier Inc.
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Neuregulin Regulation of GABAergic TransmissionFigure 3. NRG1 Increases Depolarization-Evoked [3H]GABA Release and eIPSC Amplitude
(A) Cortical slices were preloaded with [3H]GABA for 30 min in the presence of b-alanine (1 mM), an inhibitor of [3H]GABA uptake by glial cells, amino-
oxyacetic acid (0.1 mM), an inhibitor of GABA degradation, and nipecotic acid (1 mM), an inhibitor of the GABA transporter in neurons. Basal and
depolarization (20 mM KCl)-evoked release of [3H]GABA were monitored sequentially. The sum of the basal release, depolarization-evoked release,
and the residual [3H]GABA was taken as 100%. In comparison with controls (open circles), NRG1 (closed circles) had no effect on basal [3H]GABA
release, but increased depolarization-evoked [3H]GABA release.
(B) Dose-dependent potentiation of evoked [3H]GABA release. Raw data of a representative experiment are presented in Figure S1A.
(C) Representative traces of mIPSCs in pyramidal neurons in prefrontal cortical slices.
(D) Cumulative plots of mIPSC amplitudes.
(E) Cumulative plots of mIPSC frequencies.
(F) No effect of NRG1 on mIPSCs in pyramidal neurons in prefrontal cortical slices (n = 12).
(G) Increased eIPSCs in NRG1-treated slices. (Top) Representative eIPSCs of control, NRG1-treated, or NRG1-treated/washed slices. (Bottom)
Quantitative analysis of eIPSC amplitudes. n = 12, *p < 0.01.
(H) Dose-dependent effect of NRG1 on eIPSCs. n = 6, *p < 0.05, **p < 0.01.
(I) Denatured NRG1 failed to increase depolarization-evoked [3H]GABA release and eIPSC amplitude. n = 8 for [3H]GABA release; for eIPSCs, n = 6 for
control, NRG1, and denatured NRG1, and n = 4 for BDNF. *p < 0.05, #p < 0.05; **p < 0.05, ##p < 0.01.lethality can be genetically rescued by expressing ErbB4
under a cardiac-specific myosin promoter (Tidcombe
et al., 2003). This line of mice (ErbB4/ht+), however,
does not express ErbB4 in the brain (Figures 7A and 7B)or other noncardiac tissues (data not shown). Ablation of
the ErbB4 gene had no effect on basal and depolariza-
tion-evoked [3H]GABA release (Figure 7C). However, un-
like in control slices, NRG1was unable to increase evoked(E and F) Quantitative analysis of ErbB4 clusters with GAD65 and with VGAT, and VGAT and GAD65 clusters with ErbB4. More than 1100 clusters of
five independent sections were scored. Shown are means ± SEM.
(G and H) Specificity characterization of anti-ErbB4 antibodies. Coronal sections of prefrontal cortex of ErbB4+/+ht+ and ErbB4/ht+ mice were
incubated with the anti-ErbB4 antibodies 0618 and sc-283. Immunoactivity was visualized by Alexa-conjugated secondary antibodies.Neuron 54, 599–610, May 24, 2007 ª2007 Elsevier Inc. 603
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Neuregulin Regulation of GABAergic TransmissionFigure 4. Effects of NRG1 on Presynaptic
Terminals
(A) NRG1 increases depolarization-evoked
[3H]GABA release from synaptosomes.
[3H]GABA-loaded cortical synaptosomes were
treated with 5 nM NRG1 with (evoked) or with-
out (basal) 20 mM KCl. [3H]GABA release was
assayed 10min after NRG1 stimulation. Shown
are means ± SEM of six individual experiments
in triplicate. *p < 0.05, **p < 0.01.
(B) NRG1 reduces PPRs of GABAergic trans-
mission in the prefrontal cortex. (Left) Averaged
traces of eight consecutive recordings induced
by paired stimuli (10 s apart) separated by indi-
cated interpulse intervals. (Right) PPRs as
a function of interpulse intervals. The ampli-
tudes of the first and second IPSCs were mea-
sured as indicated in the inset. n = 6, *p < 0.05.[3H]GABA release and eIPSC amplitude in ErbB4/ht+
slices (Figures 7C and 7D). These observations identify
an important role of ErbB4 in NRG1 regulation of evoked
GABA release.
DISCUSSION
Themajor findings of this study are as follows. First, ErbB4,
a receptor for NRG1, is present in GABAergic terminals of
the prefrontal cortex. Second, NRG1 facilitates evoked
release of GABA from slices of the prefrontal cortex, but
has no effect on basal GABA release. Third, the potentia-
tion effect of NRG1 must require ErbB4 because it was
blocked by the ErbB4 inhibitor AG1478 andwas abolished
in cortical slices of ErbB4mutantmice. In addition, wepro-
vided evidence that evoked GABA release and eIPSCs in
the absence of exogenous NRG1 were blocked by inhibi-
tors of NRG1 signaling, suggesting a role of endogenous
NRG1 in regulating GABA neurotransmission. Together,
these results identify a novel function of NRG1—regulation
of GABAergic transmission via presynaptic ErbB4 recep-
tors. These results suggest that NRG1 may regulate the
activity of cortical interneurons, providing insight into po-
tential mechanisms by which this trophic factor regulates
synaptic plasticity and pathogenesis of schizophrenia
and epilepsy.
NRG1 and Neurotransmission at Excitatory
and Inhibitory Synapses
NRG1 has been shown to regulate differentiation of neural
cells, neuronal navigation, and neuron survival in develop-
ing CNS (Buonanno and Fischbach, 2001; Corfas et al.,
2004). In the peripheral nervous system, NRG1 signaling604 Neuron 54, 599–610, May 24, 2007 ª2007 Elsevier Inc.is implicated in Schwann cell differentiation and myelina-
tion, muscle spindle development, and synapse-specific
expression of AChR subunit genes (Adlkofer and Lai,
2000; Fischbach and Rosen, 1997; Hippenmeyer et al.,
2002; Si et al., 1996). Interestingly, NRG1 and its receptor
ErbB kinases are continuously expressed in various brain
regions, including the prefrontal cortex, hippocampus,
cerebellum, oculomotor nucleus, superior colliculus, red
nucleus, substantia nigra, and pars compacta (Lai and
Lemke, 1991; Law et al., 2004; Yau et al., 2003). Moreover,
ErbB4 colocalizes with PSD-95 and NMDA receptors in
hippocampal neurons (Garcia et al., 2000; Huang et al.,
2000). Furthermore, NRG1 signaling may be increased
by the interaction of ErbB4 with PSD-95 (Huang et al.,
2000). These observations suggest that NRG1 may play
a role in synaptic plasticity, maintenance or regulation of
synaptic structure, or some combination thereof in adult
brain. Indeed, we found that NRG1 blocks induction of
long-term potentiation (LTP) at Schaffer collateral-CA1
synapses (Huang et al., 2000). NRG1 can depotentiate
LTP at hippocampal CA1 synapses and reduce whole-
cell NMDA receptor, but not AMPA receptor, currents in
prefrontal cortex pyramidal neurons (Gu et al., 2005;
Kwon et al., 2005). Recently, ErbB4 has been shown to
play a key role in activity-dependent maturation and plas-
ticity of excitatory synaptic structure and function (Li et al.,
2007).
This study provides evidence that ErbB4 is present
at GABAergic terminals in the prefrontal cortex. The iden-
tification of the subtype or subtypes of GABA interneurons
that express ErbB4 will require further investigation.
Interestingly, ErbB4 colocalizes with GAD-GFP in GIN
mice. An earlier study demonstrated that hippocampal
Neuron
Neuregulin Regulation of GABAergic TransmissionFigure 5. Suppression of NRG1-Enhanced GABA Release by Ecto-ErbB4
(A) Ecto-ErbB4 inhibition of NRG1 activation of ErbB4 in GAD65-positive cortical neurons. Cortical neurons were pretreated with ecto-ErbB4 for
10 min prior to the addition of NRG1 (5 nM, final concentration) for another 10 min, fixed, and stained with anti-p-ErbB4 and anti-GAD65 antibodies
that were visualized with Alexa 594 and FITC-coupled secondary antibodies, respectively. Scale bar, 20 mm.
(B) Quantitative analysis of data in (A). Images were captured with a Zeiss LSM confocal microscope and analyzed by Image J software (NIH). Ecto-
ErbB4 treatment inhibits NRG1-induced ErbB4 phosphorylation. n = 7, *p < 0.05.
(C) Ecto-ErbB4 inhibition of eIPSCs. Cortical slices were treatedwith sequential addition of NRG1 (5 nM) and ecto-ErbB4 (1 mg/ml and 2 mg/ml) (all final
concentrations). eIPSCs were recorded as in Figure 3G. Shown are data from a representative experiment. On the top are averaged traces before (a)
and after (b) NRG1, and after different dosages of ecto-ErbB4 ([c] and [d], 1 and 2 mg/ml, respectively).
(D) Inhibition by ecto-ErbB4 of depolarization-evoked GABA release and eIPSCs. Cortical slices were treated with 1 or 2 mg/ml ecto-ErbB4 for 10 min
prior to assays of [3H]GABA and eIPSCs. n = 5 for [3H]GABA release, n = 6 for eIPSCs. *p < 0.01 and #p < 0.01 for [3H]GABA release and eIPSCs,
respectively.GAD-GFP-labeled neurons of these mice are mostly so-
matostatin positive (Oliva et al., 2000). Whether GFP-
labeled neurons in the prefrontal cortex are somatostatin
positive was not characterized in detail. Nevertheless,
we found that NRG1 activates ErbB4 and regulates
GABAergic transmission. This trophic factor has no effect
on basal GABA release but increases GABA release
evoked by neuronal activation. More work is needed to
determine whether NRG1 regulates neurotransmission of
other GABAergic neurons. Because glutamatergic neuro-
transmission can be regulated by NRG1 (Gu et al., 2005; Liet al., 2007) and because glutamatergic activity is known
to increase GABAergic transmission (Belan and Kostyuk,
2002), it is possible that NRG1 regulation of evoked
GABA releasemay bemediated by a glutamatergic mech-
anism. Our results, however, suggest otherwise; NRG1
enhancement of evoked [3H]GABA release was not atten-
uated by inhibitors of NMDA and AMPA receptors. More-
over, NRG1 enhanced eIPSCs in the presence of these
inhibitors. Therefore, we propose that NRG1 regulates
GABA release by directly activating ErbB4 receptors
on presynaptic terminals. The presence of ErbB4 inNeuron 54, 599–610, May 24, 2007 ª2007 Elsevier Inc. 605
Neuron
Neuregulin Regulation of GABAergic TransmissionFigure 6. Inhibition of ErbB4 Blocks
NRG1 Potentiation of GABA Release
(A) NRG1 activation of ErbB4 was inhibited by
AG1478, but not AG879. Cortical neurons
were treated with 5 mM AG1478, an inhibitor
of ErbB4, or AG879, an inhibitor of ErbB2, for
10min prior to the addition of NRG1 (5 nM, final
concentration). Neurons were fixed and
stained with phospho-ErbB4 and GAD65 anti-
bodies, and visualized with Alexa 594 and
FITC-coupled secondary antibodies, respec-
tively. Scale bar, 20 mm.
(B) Quantitative analysis of data in (A). n = 8,
*p < 0.05.
(C) Inhibition of NRG1 enhancement of evoked
GABA release by AG1478. Cortical slices
were treated with 5 mM AG1478 or AG879 for
10 min prior to assays of [3H]GABA or eIPSC
recording. n = 5 for [3H]GABA release, n = 6
for eIPSCs. *p < 0.05, #p < 0.05; **p < 0.01,
##p < 0.01.GAD-GFP-positive puncta-ring-like structures and the
colocalization with GAD65 and VGAT provide anatomical
evidence in support of this notion. Moreover, NRG1 was
able to increase depolarization-evoked GABA release
from synaptosomes that were free of interneural network,
suggesting that the regulatory machinery for NRG1 was
present in presynaptic terminals. Furthermore, NRG1 de-
creases PPRs of eIPSCs in response to two consecutive
stimulations, suggesting that it may facilitate vesicle re-
lease evoked by neuronal activation of interneurons.
NRG1, ErbB4, and Neurological
and Psychiatric Disorders
Schizophrenia exhibits familial characteristics, which
suggests a strong genetic component. Disturbances in
GABAergic neurotransmission have been thought to be
a pathologic mechanism of schizophrenia. Postmortem
studies of patient brains reveal decreased levels of the
mRNA encoding GAD67 (Hashimoto et al., 2003) and
the GABA transporter GAT-1 (Ohnuma et al., 1999). On
the other hand, GABA-A receptor mRNA was shown to606 Neuron 54, 599–610, May 24, 2007 ª2007 Elsevier Inc.be increased in the prefrontal cortex (Ohnuma et al.,
1999). Furthermore, treatment of schizophrenia with anti-
epileptic drugs that target GABAergic transmission has
shown positive results (Hosak and Libiger, 2002).
This paper provides evidence that endogenous NRG1
plays a role in maintaining evoked GABA release. First,
treatment with ecto-ErbB4 alone attenuated evoked
GABA release, presumably by neutralizing endogenous
NRG1. Second, inhibition of ErbB4 reduced evokedGABA
release in the absence of exogenous NRG1. In light of the
fact that interneuron activity in vivo could be high (Mount-
castle et al., 1969), it is likely that NRG1 plays an important
role in controlling neuronal activity in the brain. These data
are consistent with expression of NRG1 by cortical pyra-
midal neurons and ErbB4 by interneurons. While ErbB4
is expressed in interneurons throughout the cortex, dis-
tinct isoforms of NRG1 appear to be expressed in a lam-
ina-specific and largely nonoverlapping manner in the
cortex. The readily available NRG1maymaintain basal ac-
tivity-dependent GABAergic transmission. Interestingly,
NRG1 or ErbB4 heterozygotes show hyperactivity in an
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ReleaseWasDiminished in ErbB4Mutant
Mice
(A) Genotyping of heart-rescued ErbB4/
mice. Transgenic mice (ht+) expressing ErbB4
under the control of the MHC promoter
were crossed with ErbB4+/ mice to generate
ErbB4/;ErbB4HEART (ErbB4/ht+) (Tid-
combe et al., 2003). The ErbB4 wild-type
allele yields150 bp, whereas themutant allele
yields 320 bp. The heart rescue transgene
yields 500 bp.
(B) Western blots showing that ErbB4 was not
expressed in the brains from ErbB4/ht+
mice. Equal loading was shown by immuno-
blotting for actin.
(C) NRG1 enhancement of depolarization-
evoked GABA release was abolished in
ErbB4/ht+ cortical slices. [3H]GABA release
was assayed as in Figure 3A. n = 6.
(D) NRG1 potentiation of eIPSCs was lost in
ErbB4 mutant mice. Cortical slices of control
(ErbB4+/+ht+) and ErbB4/ht+ mice were re-
corded for eIPSCs. Shown are normalized
eIPSC amplitudes. n = 6, *p < 0.05. The eIPSC
amplitudes in ErbB4+/+ht+ and ErbB4/ht+
were 1014 ± 170 and 598 ± 160 pA, respec-
tively. n = 17, p < 0.01.open field (Gerlai et al., 2000; Stefansson et al., 2002). Fur-
ther investigation of NRG1’s role in regulating GABA trans-
mission could be useful in understanding the pathogene-
sis of schizophrenia and epilepsy.
EXPERIMENTAL PROCEDURES
Reagents and Animals
The NRG1 used is a recombinant polypeptide containing the entire
EGF domain of the b-type NRG1 (rHRG b177–244) from Dr. Mark
Sliwkowski (Holmes et al., 1992). It was prepared in 1% bovine serum
albumin (BSA). BDNF was a gift from Regeneron Pharmaceuticals.
The ectodomain of ErbB4 (aa 1–659, ecto-ErbB4) was subcloned
into pC4DNA/Fc to generate pErbB4ex/Fc. Stable HEK293 cells ex-
pressing ecto-ErbB4 were generated and cultured in IgG-low medium
for condition media collection. ErbB4ex/Fc was purified by a HiTrap
column (Amersham). AG1478 and AG879 were from Calbiochem;
poly-L-lysine, nipecotic acid, b-alanine and TMPH (2,2,6,6,-Tetrame-
thylpiperidin-4-yl heptanoate) from Sigma; DL-AP5, CNQX, TTX, bicu-
culline, LY341495, ipratropium, nicergoline, sotalol, metergoline, MDL
72222, RS 23597-190, and L-741742 from Tocris Bioscience; and
aminooxyacetic acid from Chemika. When necessary, chemicals were
dissolved in dimethylsulfoxide (DMSO, Sigma); the final concentration
of DMSO was 0.001% or less when applied to brain slices. Antibodies
were from Sigma (GAD65, G1166); Cell Signaling Technology [ErbB4,
#4795; p-ErbB4 (Y1284), #4757]; Transduction Labs (phosphotyro-
sine, 610024); NeoMarkers (ErbB2, MS-303-PO; ErbB3, MS-229-PO);
Santa Cruz Biotechnology (ErbB4, sc-283); and Synaptic Systems
(VGAT, 131003). ErbB4/ht+ mice were kindly provided by Martin
Gassmann (Tidcombe et al., 2003). GAD-GFP mice were from the
Jackson Lab.
[3H]GABA Release
[3H]GABA release from cerebral cortical slices was assayed as de-
scribed previously (Woo et al., 2002). Briefly, male Sprague-Dawley
rats (200–250 g) or ErbB4+/+ht+ and ErbB4/ht+ mice were decapi-tated; cerebral cortices were dissected out and sliced with a McIlwain
tissue chopper. Slices (0.253 0.25 mm) were preincubated for 15 min
at 37C in 10ml of oxygenated Krebs-HEPES buffer (KHB, pH 7.4) con-
taining 25 mM HEPES-sodium salt, 100 mM NaCl, 5 mM KCl, 1.2 mM
MgCl2, 2.5 mM CaCl2, and 10 mM glucose. Slices were incubated
for 30 min with 50 nM [3H]GABA (Perkin-Elmer Life Sciences, 33.7
Ci/mmol) in KHB containing 1 mM b-alanine to prevent [3H]GABA up-
take by glial cells. For basal GABA release, slices were incubated in
KHB for 10 min, after which aliquots of the medium were collected.
For depolarization-evoked GABA release, slices were incubated with
KHB containing 20 mM KCl for 10 min in the presence or absence of
NRG1 (5 nM, unless otherwise indicated). In some experiments, inhib-
itors or vehicle were added 10 min prior to NRG1 stimulation. Medium
was collected and counted in scintillation solution by a b counter. Sli-
ces were incubated in 0.2 N HCl for 45 min to extract residual radioac-
tivity. The sum of basal release, the release in the presence of KCl
(evoked), and the residual [3H]GABA was taken as 100%. Aminooxy-
acetic acid (0.1 mM), an inhibitor of GABA degradation, and nipecotic
acid (1 mM), an inhibitor of the GABA transporter in neurons, were
present in all solutions.
To measure GABA release from synaptosomes, cerebral cortex was
isolated from adult rats and homogenized in 10 volumes of the homog-
enization buffer (0.32 M sucrose, 5 mM HEPES-NaOH [pH 7.4], and
1 mM EDTA) with glass-Teflon homogenizer (Turner and Goldin, 1989).
Homogenates were cleared by low-speed centrifugation (1000 3 g
for 10 min) to remove nuclear fractions and cell debris. The superna-
tant was centrifuged at 14,5003 g for 20 min and the resulting synap-
tosomal pellet (P2) was resuspended in ice-cold oxygenated KHB
buffer to 2 mg protein/ml. Synaptosomes were incubated at 37C for
10 min before the addition of [3H]GABA (33.7 Ci/mmol, 50 nM) in oxy-
genated KHB for 10 min. The loading reaction was stopped by a cen-
trifugation at 12,000 3 g for 1 min and the pellet resuspended to 1 mg
protein/ml with ice-cold oxygenated KHB. To measure [3H]GABA re-
lease, synaptosomes (50 mg protein in 100 ml) were stimulated without
(basal) or with (evoked) 20 mM KCl at 37C for 10 min and centrifuged
at 12,000 3 g for 1 min at 4C. Aliquots of the supernatant and SDS-
solubilized pellets were counted. The sum of the radioactivity in the
supernatant and pellets was taken as 100%.Neuron 54, 599–610, May 24, 2007 ª2007 Elsevier Inc. 607
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Transverse prefrontal cortical slices (0.3mm)were prepared fromP28–
P36 mice using a Vibroslice (Leica VT 1000S) in the ice-cold solution,
which contained 2.5 mM KCl, 1.25 mM NaH2PO4, 10 mM MgSO4,
0.5 mMCaCl2, 26mMNaHCO3, 10mMglucose, and 230mM sucrose.
Slices were allowed to recover for at least 2 hr in ACSF (1 hr at 34C
followed by 1 hr at 22C) in a solution containing 126 mM NaCl,
2.5 mM KCl, 1.25 mM NaH2PO4, 2 mM MgSO4, 2 mM CaCl2, 26 mM
NaHCO3, and 10 mM glucose. Slices were placed in the recording
chamber and superfused (1.5 ml/min) with ACSF at 34C. All solutions
were saturated with 95%O2/5%CO2. Neurons were visualized with an
IR-sensitive CCD camera with a 403water-immersion lens (Zeiss, Ax-
ioskop2 Fsplus) and recorded using whole-cell voltage-clamp tech-
niques (MultiClamp 700B Amplifier, Digidata 1320A analog-to-digital
converter) and pClamp 9.2 software (Axon Instruments). Glass pi-
pettes were filled with the solution containing 125 mM Cs-gluconate,
10mMCsCl, 1mMMgCl2, 10mMHEPES, 1mMEGTA, 0.1mMCaCl2,
10mM sodium phosphocreatine, 4mMMg-ATP, 0.3mMGTP, 0.2mM
leupeptin, and 5 mM lidocaine N-ethylchloride (QX314) (pH 7.2, with
the osmolarity adjusted to 280 mOsm with sucrose). The resistance
of pipettes was 2–3 MU. For mIPSC recording, QX314 was omitted
in the pipette filling solution, whereas 1 mM TTX was included in the
superfusing solution. eIPSCs were generated with a two-concentric
bipolar stimulating electrode (25 mm pole separation; FHC, ME) posi-
tioned 100 mm from the neuron under recording. Single or paired
pulses of 0.2mswere delivered at 0.1Hz and synchronized using aMa-
ter-8 stimulator (A.M.P.I). The holding potential for both mIPSCs and
eIPSCs was 65 mV. All experiments were done at 34C in the pres-
ence of 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 mM) and
AP-5 (50 mM) to block AMPA/NMDA receptors. Data were collected
when series resistance fluctuated within 15% of initial values (8–15
MU), they were filtered at 2 kHz, and they were sampled at 10 kHz.
Cell Culture
Primary cortical neuronswere cultured as described previously (Huang
et al., 2000). Briefly, cerebral cortex was dissected out of Sprague-
Dawley rat embryos (E18) and dissociated by gentle trituration in PBS
(Cellgro). Cells were seeded on poly-L-lysine-coated 12-well plates
and cultured in Neurobasal media (Gibco). Experiments were per-
formed 14 days after seeding (DIV14). C2C12 cells were obtained
from E. S. Ralston (NIH) and cultured as previously described (Si
et al., 1996). Togenerate ecto-ErbB4,HEK293cellswere cotransfected
with pC4-B4Ex/Fc, which expresses the entire ectodomain fused with
the Fc fragment, and pEGFP-C1, which contains the neomycin resis-
tance gene at a ratio of 10:1. Cells resistant to G418 (0.4 mg/ml) were
cloned. Cells were cultured in 2% low Ig fetal bovine serum to collect
condition medium. Ecto-ErbB4 was purified by chromatography using
HiTrap protein G beads (Amersham).
Immunoprecipitation and Western Blotting
Immunoprecipitation was carried out as previously described (Huang
et al., 2000). Briefly, cell lysates (1 mg of protein) were incubated
with indicated antibodies (1–2 mg) at 4C for 1 hr with constant rocking
in 1 ml of the modified RIPA buffer (50 mM Tris-HCl [pH 7.4], 150 mM
NaCl, 1% NP-40, 0.25% sodium-deoxycholate, 1 mM PMSF, 1 mM
EDTA, 1 mg/ml aprotinin, leupeptin, and pepstatin protease inhibitors).
Samples were then incubated at 4C for 1 hr with agarose beads (1:1
slurry, 50 ml) conjugated with protein A (for rabbit antibodies) or G (for
mouse antibodies). Bound proteins were resolved by SDS-PAGE and
transferred to nitrocellulose membrane, which was blocked with TBS
containing 5% nonfat dry milk and 0.05% Tween 20 for 1 hr. Themem-
brane was then incubated overnight at 4C with primary antibodies
and developed by horseradish peroxidase-conjugated secondary
antibodies and enhanced chemiluminescence system (Amersham
Pharmacia).608 Neuron 54, 599–610, May 24, 2007 ª2007 Elsevier Inc.In Situ Hybridization
In situ hybridization was performed essentially as previously described
(Simmons et al., 1989), with minor modifications. Adult Sprague-Daw-
ley rats were perfused for 20 min with 4% paraformaldehyde in 0.1 M
sodium borate buffer (pH 9.5). Sagittal sections (30 mm) were cut on
a sliding microtome and mounted on gelatin and poly-L-lysine-coated
slides. Tissue sections were fixed for 30 min in 10% buffered formalin
andwashed in 50mMKPBS prior to prehybridization. ErbB4 sequence
#1009-1931 (accession # NM-021687), NRG1 type I/II sequence #345-
845 (accession # NM-031588), and NRG1 type III sequence #555-1321
(accession #AF194438) were subcloned in pCRScript. Plasmids were
digested with NotI, SpeI, and EcoRI, respectively, for the production of
individual antisense RNAs using T7 RNA polymerase. Transcriptions
were performed using 125 mCi 33P-UTP (2000–4000 Ci/mmole, NEN).
After hybridization, the sections were defatted in xylene, rinsed in
100% ethanol and then 95% ethanol, air dried, and dipped in NTB2
emulsion (Kodak) diluted 1:1 with water. The slides were exposed for
2–5 weeks and developed in Kodak D-19 developer. All images were
captured with a Hamamatsu Orca ERCCD camera using dark-field mi-
croscopy on an Olympus BX-51 microscope at 1.25 3 magnification.
Immunostaining
Immunostaining of rat cortical neurons (E17, DIV14) was performed as
previously described (Huang et al., 2000). Briefly, neurons were fixed
with 4% paraformaldehyde and 4% sucrose in PBS for 20 min, and
permeabilized by incubation in PBS containing 1% BSA and 0.1% Tri-
ton X-100 for 30 min at room temperature. After washing, neurons
were incubated in the buffer containing antibodies against phospho-
ErbB4 (1:200), GAD65 (1:200), or both for 1 hr at room temperature.
Brain sections (20 mm) were fixedwith 10% formaldehyde and blocked
in 5% BSA/1% normal goat serum (Ren et al., 2004). Sections were in-
cubated overnight at 4C in PBS containing rabbit anti-ErbB4 with or
without anti-GAD65 or VGAT. Fluorochrome-conjugated secondary
antibodies were used to visualize the immunoreactivity with a confocal
microscope.
Statistical Analysis
Data were presented asmean ± SEM of three or more independent ex-
periments. For multiple group comparisons, statistical differences
were calculated by one-way ANOVA followed by Dunnett’s test. For
comparison of means from the same group of cells, Student’s paired
t test was used. mIPSCs were analyzed by the Kolmogorov-Smirnov
(K-S) test. Values of p < 0.05 were considered significant.
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/54/4/599/DC1/.
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